4G Clinical Archives - Medical Design Sourcing

Image courtesy of Pixabay

The clinical trial landscape has evolved significantly in the past two years. But given the quick embrace of decentralized clinical trials and growing traction of apps, digital health and other technologies in the space, it can be difficult to separate hype from reality.

To learn more about the evolving landscape, we caught up with Libbi Rickenbacher, director of strategy at 4G Clinical, to discuss the ongoing impact of the pandemic, decentralized clinical trials and other relevant trends.

Radical shifts in clinical trials?

The pandemic has undoubtedly disrupted clinical trials, leading to delays and outright cancellation of scores of studies. It may seem like a radical shift, but there was also self-preservation at work, Rickenbacher said.

“For some of those studies, maybe it was better for them to cancel,” she said. “It was very unfortunate for the patients, but you …

Image courtesy of Pixabay

The clinical trial space had one of its most significant disruptions in decades in the early days of the pandemic. Now, some clinical trials are normalizing, but decentralized clinical trials are also growing.

To learn more about what is likely on the horizon for clinical trials in 2022, we reached out to Jan Pieter Kappelle, VP of strategy of 4G Clinical. Kappelle is optimistic about continued growth of decentralized clinical trials and the spread of digitization throughout the supply chain.

1. DCT trial designs will continue to grow

The adoption of decentralized clinical trials (DCT) surged in the early days of the pandemic. “When we started up in this pandemic almost two years ago, studies really ground to a halt,” Kappelle said. As drug companies scrambled to adapt, many embraced a direct-to-patient (DtP) model for patients.

4G Clinical

What’s really happening with clinical trial innovation?

4 clinical trial predictions for 2022